Press Releases

 
Press Releases
  Date Title and Summary View
Nov 21, 2014
Treatment with Patiromer FOS Resulted in a Decrease in Elevated Serum Potassium Levels in CKD Patients on RAAS Inhibitors Normal Potassium Levels Maintained More Effectively in Patiromer FOS Treated Patients than with Placebo More Patiromer FOS Treated Patients Able to Continue on RAAS Inhibitor Therapy than with Placebo, a pre...
Nov 20, 2014
REDWOOD CITY, Calif., Nov. 20, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on November 17, 2014, the compensation committee of the company's board of directors granted new employee Scott Garland, the company's senior vice president and chief commercial officer, an option to purchase 100,00...
Nov 17, 2014
REDWOOD CITY, Calif., Nov. 17, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that data from clinical trials of the company's lead product candidate, Patiromer for Oral Suspension (Patiromer FOS), were presented at the American Society of Nephrology (ASN) Annual Meeting held last week in Philadelp...
Nov 12, 2014
REDWOOD CITY, Calif., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that John A. Orwin, president and chief executive officer, will present at the Stifel Healthcare Conference on November, 19, 2014 at 8:00 a.m. ET. To access the live webcasts and subsequent archived recordings of...
Nov 10, 2014
REDWOOD CITY, Calif., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2014. Net loss for the third quarter 2014 was $19.4 million, or $0.57 per share, compared to $25.6 million, or $79.91 per share, for the comparable period in 201...
Nov 6, 2014
REDWOOD CITY, Calif., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), today announced the launch of a new website entitled "Hyperkalemia Clinical Insights" (www.hyperkalemiainsights.com), which was developed by the company as an educational resource for healthcare professionals. Hyperkalemia is a serious condition defined as abnormall...
Nov 4, 2014
REDWOOD CITY, Calif., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that data from clinical trials of the company's lead product candidate, Patiromer for Oral Suspension (Patiromer FOS), as well as data on the relationship of high potassium levels and mortality, will be presented at the A...
Nov 3, 2014
REDWOOD CITY, Calif., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), today announced that Scott Garland has joined the company as senior vice president and chief commercial officer. Garland, a seasoned executive with over 20 years of biotechnology and pharmaceutical experience, has extensive expertise in launching products and buildi...
Oct 30, 2014
REDWOOD CITY, Calif., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that management will present at the Nomura Biotechnology Conference November, 6, 2014 at 2:45 p.m. ET. To access the live webcasts and subsequent archived recordings of these presentations, please visit Relypsa's web...
Oct 22, 2014
REDWOOD CITY, Calif., Oct. 22, 2014 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval to market Patiromer for Oral Suspension (Patiromer FOS) for the treatment of hyperkalemia, a serious condition defined as abn...
Page:
1
... NextLast
= add release to Briefcase